Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NORAD, LINC00657, ASHGA5P032173 |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qRT-PCR, Western blot, in vitro knockdown, Luciferase reporter assay |
| Sample | Human CRC cancer cell lines (SW480 and HCT116) |
| Expression Pattern | up-regulated |
| Function Description | NORAD served as a competing endogenous RNA for miR-202-5p.We found that there was an inversely relationship between the expression of NORAD and miR-202-5p in CRC tissues.Moreover, overexpression of miR-202-5p in SW480 and HCT116 cells significantly inhibited cellular proliferation,migration and invasion.Taken together,our study demonstrated NORAD/miR-202-5p axis plays a pivot function on CRC progression. |
| Pubmed ID | 29471886 |
| Year | 2018 |
| Title | LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |